The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Roy M. Gulick

Weill-Cornell Medical College

New York

NY 10065

USA

[email]@med.cornell.edu

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Weill-Cornell Medical College, New York, NY 10065, USA. 2008
  • Weill Medical College of Cornell University, 525 East 68th Street, New York, NY 10021, USA. 2000 - 2007
  • Division of International Medicine and Infectious Diseases, Weill Medical College of Cornell University, New York, NY 10021, USA. 2000 - 2007
  • Weill Medical College of Cornell University and New York University School of Medicine, Cornell Clinical Trials Unit, New York, NY 10021, USA. 2001

References

  1. Maraviroc for previously treated patients with R5 HIV-1 infection. Gulick, R.M., Lalezari, J., Goodrich, J., Clumeck, N., DeJesus, E., Horban, A., Nadler, J., Clotet, B., Karlsson, A., Wohlfeiler, M., Montana, J.B., McHale, M., Sullivan, J., Ridgway, C., Felstead, S., Dunne, M.W., van der Ryst, E., Mayer, H. N. Engl. J. Med. (2008) [Pubmed]
  2. Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virological suppression. Gulick, R.M., Lalama, C.M., Ribaudo, H.J., Shikuma, C.M., Schackman, B.R., Schouten, J., Squires, K.E., Koletar, S.L., Pilcher, C.D., Reichman, R.C., Klingman, K.L., Kuritzkes, D.R. AIDS (2007) [Pubmed]
  3. Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211. Gulick, R.M., Su, Z., Flexner, C., Hughes, M.D., Skolnik, P.R., Wilkin, T.J., Gross, R., Krambrink, A., Coakley, E., Greaves, W.L., Zolopa, A., Reichman, R., Godfrey, C., Hirsch, M., Kuritzkes, D.R. J. Infect. Dis. (2007) [Pubmed]
  4. Antiretroviral management of treatment-naive patients. Gulick, R.M. Infect. Dis. Clin. North Am. (2007) [Pubmed]
  5. New antiretroviral agents. Siegel, L., Gulick, R.M. Curr. Infect. Dis. Rep (2007) [Pubmed]
  6. Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial. Gulick, R.M., Ribaudo, H.J., Shikuma, C.M., Lalama, C., Schackman, B.R., Meyer, W.A., Acosta, E.P., Schouten, J., Squires, K.E., Pilcher, C.D., Murphy, R.L., Koletar, S.L., Carlson, M., Reichman, R.C., Bastow, B., Klingman, K.L., Kuritzkes, D.R. JAMA (2006) [Pubmed]
  7. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. Gulick, R.M., Ribaudo, H.J., Shikuma, C.M., Lustgarten, S., Squires, K.E., Meyer, W.A., Acosta, E.P., Schackman, B.R., Pilcher, C.D., Murphy, R.L., Maher, W.E., Witt, M.D., Reichman, R.C., Snyder, S., Klingman, K.L., Kuritzkes, D.R. N. Engl. J. Med. (2004) [Pubmed]
  8. New Antiretroviral Agents for the Treatment of HIV Infection. Marks, K., Gulick, R.M. Curr. Infect. Dis. Rep (2004) [Pubmed]
  9. New antiretroviral drugs. Gulick, R.M. Clin. Microbiol. Infect. (2003) [Pubmed]
  10. Antiretroviral Therapy: When and What to Start-- An American Perspective. Wilkin, T.J., Gulick, R.M. Curr. Infect. Dis. Rep (2003) [Pubmed]
  11. Structured treatment interruption in patients infected with HIV: a new approach to therapy. Gulick, R.M. Drugs (2002) [Pubmed]
  12. Durability of response to treatment among antiretroviral-experienced subjects: 48-week results from AIDS Clinical Trials Group Protocol 359. Gulick, R.M., Hu, X.J., Fiscus, S.A., Fletcher, C.V., Haubrich, R., Cheng, H., Acosta, E., Lagakos, S.W., Swanstrom, R., Freimuth, W., Snyder, S., Mills, C., Fischl, M., Pettinelli, C., Katzenstein, D. J. Infect. Dis. (2002) [Pubmed]
  13. New drugs for HIV therapy. Gulick, R.M., Staszewski, S. AIDS (2002) [Pubmed]
  14. Indinavir, nevirapine, stavudine, and lamivudine for human immunodeficiency virus-infected, amprenavir-experienced subjects: AIDS Clinical Trials Group protocol 373. Gulick, R.M., Smeaton, L.M., D'Aquila, R.T., Eron, J.J., Currier, J.S., Gerber, J.G., Acosta, E., Sommadossi, J.P., Tung, R., Snyder, S., Kuritzkes, D.R., Murphy, R.L. J. Infect. Dis. (2001) [Pubmed]
  15. New Drugs for the Treatment of HIV Infection. Lee, K., Gulick, R.M. Curr. Infect. Dis. Rep (2001) [Pubmed]
  16. 3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine. Gulick, R.M., Mellors, J.W., Havlir, D., Eron, J.J., Meibohm, A., Condra, J.H., Valentine, F.T., McMahon, D., Gonzalez, C., Jonas, L., Emini, E.A., Chodakewitz, J.A., Isaacs, R., Richman, D.D. Ann. Intern. Med. (2000) [Pubmed]
  17. Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both in human immunodeficiency virus-infected adults with virologic failure on indinavir: AIDS Clinical Trials Group Study 359. Gulick, R.M., Hu, X.J., Fiscus, S.A., Fletcher, C.V., Haubrich, R., Cheng, H., Acosta, E., Lagakos, S.W., Swanstrom, R., Freimuth, W., Snyder, S., Mills, C., Fischl, M., Pettinelli, C., Katzenstein, D. J. Infect. Dis. (2000) [Pubmed]
 
WikiGenes - Universities